Cancers · 2019 · 45 citations · 35 references
PharmacyMedicinal ChemistryPharmaceuticsAntibody EngineeringDrug DeliveryMolecular OncologyAntibody CharacterizationAntibody ConjugatesAntibody ConjugationAntibody StabilityAntibody-drug ConjugatesTherapeutic Antibody DevelopmentAntibody-drug Conjugate LinkersAntibody-drug Conjugate TherapyAntibody-drug LinkersCleavable LinkersConjugation Chemistry For AntibodiesConjugation Of Antibody FragmentsTherapeutic Antibody DesignTherapeutic Toxicity
Antibody-drug conjugate (ADC) is a novel efficient drug delivery system that has been successfully used in clinical practice, and it has become a research hotspot in the anti-tumor drug field. Acid-cleavable linkers were first used in clinical ADCs, but their structural variety (e.g., hydrazone and carbonate) is still limited, and their stability is usually insufficient. Designing novel acid-cleavable linkers for the conjugation of the popular cytotoxin monomethyl auristatin E (MMAE) has always been a significant topic. In this paper, we generate a novel, silyl ether-based acid-cleavable antibody-MMAE conjugate, which skillfully achieves efficient combination of amino-conjugated MMAE with the acid-triggered silyl ether group by introducing p-hydroxybenzyl alcohol (PHB). The stability, acid-dependence cleavage, effective mechanism, efficacy and safety of the resulting ADC were systematically studied; the results show that it exhibits a significant improvement in stability, while maintaining appropriate efficacy and controlled therapeutic toxicity. This strategy is expected to expand a new type of acid-cleavable linkers for the development of ADCs with highly potent payloads.
35
Cure of Xenografted Human Carcinomas by BR96-Doxorubicin Immunoconjugates
Pamela A. Trail, David Willner, Shirley J. Lasch et al. · Science · 1993 · 554 citations
Medicine, Oncology, Pharmacology +16